Current Valuation
N/A
As of October 8, 2025
Total Funding Raised
$14.9M
Last Round
Accelerator/Incubator

Amount undisclosed

Last Funding
Oct 2025

Funding date

Capital Efficiency
N/A

Valuation / Funding

Funding History & Valuation Timeline
Complete history of all funding rounds and valuation milestones

No funding history available

Funding data has not been imported for this company yet

Valuation Analysis

Current Valuation Metrics

Orakl Oncology is currently valued at N/A as of October 8, 2025. The company has raised a total of $14.9M in funding.

Investment Perspective

Orakl Oncology's valuation reflects investor confidence in the company's market position, growth potential, and ability to execute on its business model. Private market valuations are determined by primary funding rounds and secondary market transactions, which take into account financial performance, market conditions, and growth prospects.

Track Orakl Oncology Valuation Updates

Get notified when Orakl Oncology raises new funding or valuation changes

What is Orakl Oncology Worth in 2025?

As of 2025, Orakl Oncology is valued at N/A, based on the company's Accelerator/Incubator funding round in October 8, 2025. This valuation positions Orakl Oncology as one of the leading private companies in the sector.

Orakl Oncology Valuation History

Orakl Oncology's funding history demonstrates steady growth and investor confidence.

How Orakl Oncology Valuation is Determined

Private company valuations like Orakl Oncology's are determined through primary funding rounds led by venture capital firms, private equity investors, and strategic partners. The valuation reflects factors including:

  • Revenue growth and financial performance
  • Market opportunity and total addressable market (TAM)
  • Competitive positioning and market share
  • Management team strength and execution capability
  • Technology and intellectual property
  • Industry trends and investor sentiment

Orakl Oncology Valuation FAQs

Is Orakl Oncology profitable?

Orakl Oncology has not publicly disclosed its profitability status. Many high-growth private companies prioritize market expansion and user growth over profitability in their early stages.

How does Orakl Oncology's valuation compare to competitors?

Orakl Oncology is valued at N/A, positioning it as a major player in the space. Secondary market pricing and private market transactions provide ongoing validation of this valuation.

When will Orakl Oncology IPO?

Orakl Oncology has not announced plans for an initial public offering. Until an IPO, investors can access Orakl Oncology shares through secondary market platforms.